Abbott and Biotest sign development deal for immune disease drug - Proactive Investors USA & Canada

Abbott and Biotest sign development deal for immune disease drug Proactive Investors USA & North American country Abbott Laboratories (NYSE:ABT) and Germany's Biotest (ETR:BIO) aforementioned Tuesday they have autographed a deal to develop and commercialize a possible treatment for rheumatoid arthritis (RA) and psoriasis , sending Biotest shares ahead more than 23% in Frankfurt. ... Abbott, Biotest To Team Up connected Treatment For Arthritis, disease of the skin Wall Street Journal Abbott, Biotest seal deal concluded arthritis drug Reuters Abbott inks $470M pact for Biotest's Ph2 RA antibody program FierceBiotech PR Newswire (press release)  - hereditary Engineering News all xxxvi news articles » Link To Article